Table 3.

Mean tumor marker expression score for BCL6, BLIMP1, LMO2, and CD30 among others by tumor EBV infection status

DLBCL EBV infection statusTumor marker scorea, mean (SD)
BCL6BLIMP1LMO2CD30
 EBV− (n = 48)1.78 (1.34)0.09 (0.36)2.33 (1.55)0.62 (1.27)
 EBV+ (n = 22)0.55 (1.10)0.77 (1.27)1.09 (1.02)1.76 (1.73)
Pb<0.0010.0030.003<0.001
BCL2BAXCyclin D2Cyclin E
 EBV−1.83 (1.34)2.89 (1.37)0.02 (0.15)1.24 (1.37)
 EBV+1.33 (1.24)2.05 (1.53)0.05 (0.21)1.64 (1.33)
Pb0.2310.0160.5980.239
Ki-67FOXP1P53Survivin
 EBV−2.10 (0.79)1.25 (1.25)0.54 (1.15)2.91 (1.43)
 EBV+2.29 (1.64)0.91 (1.27)0.77 (1.02)2.71 (1.45)
Pb0.5340.3260.1100.342
P27MMP9GAL3SKP2
 EBV−0.52 (0.80)1.82 (1.66)1.58 (1.44)0.44 (1.03)
 EBV+0.64 (0.73)2.24 (1.70)1.33 (1.43)0.41 (0.91)
Pb0.3530.4950.3450.632
PKC-beta 2MUM1cMYCCD43
 EBV−2.52 (1.79)1.52 (1.50)1.46 (1.50)0.89 (1.52)
 EBV+3.00 (1.45)2.50 (1.41)1.73 (1.49)1.52 (1.89)
Pb0.2180.0120.5980.278
CD10CD44CD21
 EBV−1.08 (1.40)2.81 (1.28)1.12 (0.15)
 EBV+1.00 (1.35)2.71 (1.19)0
Pb0.9450.6020.493
  • aTumor marker score: 0, 0%–9%; 1, 10%–24%; 2, 25%–49%; 3, 50%–74%; and 4, ≥75% of DLBCL cells stained positive for the marker.

  • bP value derived from Pearson correlation coefficient statistics. Significance level for P < 0.10 after adjustment for multiple comparison is 0.004 [0.10/23 (number of markers examined) = 0.004].